Calcium hydroxylapatite for jawline rejuvenation: consensus recommendations
| Autor: | Jean-Marie Dallara, Marie-Hélène Charavel, Patrick Bui, Martine Baspeyras, Hugues Cartier, Laurent Dumas |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Injectable filler Consensus Esthetics Injections Intradermal business.industry Facial rejuvenation Dentistry Lower face Dermatology Aging face Skin Aging Surgery Durapatite Face Practice Guidelines as Topic Humans Rejuvenation Medicine Dermatologic Agents Tissue augmentation business Calcium hydroxylapatite Volume loss |
| Zdroj: | Journal of Cosmetic Dermatology. 13:3-14 |
| ISSN: | 1473-2130 |
| Popis: | SummaryBackground Age-associated volume loss is now known to play an important role in the structural changes of the aging face. In the lower face, this manifests as drooping of the corners of the mouth and jowl leading to a loss of the oval jawline of youth. Jawline reshaping by replacing volume has therefore become an indispensable component of modern facial rejuvenation. Aim Calcium hydroxylapatite (CaHA; Radiesse®, Merz Pharmaceuticals GmbH, Frankfurt, Germany) is an injectable filler with a cosmetic indication for tissue augmentation. The ability of calcium hydroxylapatite to provide immediate and long-lasting volume enhancement makes it an ideal agent for restoring an oval jawline. Method This consensus statement has been developed to assist clinicians who would like to gain more experience in the use of volumizing agents to achieve an optimal outcome with this procedure. Results Using the recently developed Merz Aesthetics Scale® for jawline, the consensus provides a treatment protocol for individuals at each stage of oval loss and presents a series of before and after images to illustrate the improvements that can be achieved. Specific recommendations for calcium hydroxylapatite including type of anesthesia, injection techniques, volume for injection, use in combination with other procedures, and expected duration of corrections are provided. Techniques for minimizing and managing expected problems and potential complications are also described. Conclusion Calcium hydroxylapatite is appropriate for treating patients at any stage of oval loss. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |